Sana Biotechnology Inc (NAS:SANA)
$ 6.91 -0.06 (-0.86%) Market Cap: 1.53 Bil Enterprise Value: 1.34 Bil PE Ratio: 0 PB Ratio: 4.07 GF Score: 39/100

Sana Biotechnology Inc at Goldman Sachs Global Healthcare Conference Transcript

Jun 14, 2022 / 11:00PM GMT
Release Date Price: $4.12 (-0.96%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Good afternoon. Thanks, everyone, for joining us. We're really pleased to have Sana here with us. And we have Steve Harr, who's President and CEO.Steve, Sana is a preclinical biotechnology company that's focused on cell engineering in a broad sense with a dual platform approach. Could you just give us a brief overview of both your ex vivo hypoimmune and in vivo fusogen technologies? And remind us how your platform is differentiated versus others?

Questions & Answers

Steven D. Harr
Sana Biotechnology, Inc. - President, CEO & Director

Yes. First of all, thank you, Salveen, for having us. It's a beautiful location, and it's always nice to get out and see people again. And I appreciate everybody who's been going at it for a long day for joining us, and we'll try to make sure this is hugely entertaining part of your day and worthwhile, so thank you.

So we will make forward-looking statements just on the -- so everybody, so we do spend time running our risk factors and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot